RayKnowChina Research Map
Shortlist0

NanningGuangxi Medical University

First Affiliated Hospital of Guangxi Medical University

广西医科大学第一附属医院

Listed for 27 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at First Affiliated Hospital of Guangxi Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌54 papers led5 open trials led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
  3. Hepatocellular carcinoma肝细胞癌134 papers led
  4. Stomach cancer胃癌46 papers led
  5. Hepatoblastoma肝母细胞瘤1 paper led
  6. Chordoma脊索瘤0 papers led
  7. Osteosarcoma骨肉瘤37 papers led
  8. Neuroblastoma神经母细胞瘤3 papers led
  9. Ewing sarcoma尤文肉瘤1 paper led
  10. Multiple myeloma多发性骨髓瘤11 papers led
  11. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症3 papers led
  12. Beta thalassaemiaβ 地中海贫血25 papers led1 open trial led
  13. Haemophilia A血友病 A2 papers led
  14. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病3 papers led
  15. Myasthenia gravis重症肌无力5 papers led
  16. Moyamoya disease烟雾病4 papers led
  17. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎11 papers led
  18. Takayasu arteritis大动脉炎2 papers led
  19. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  20. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  21. Duchenne muscular dystrophy杜氏肌营养不良2 papers led
  22. Behçet disease白塞病0 papers led
  23. IgA nephropathyIgA 肾病4 papers led
  24. Osteogenesis imperfecta成骨不全症1 paper led
  25. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  26. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  27. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Retinoblastoma, Gastrointestinal stromal tumour, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 54 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 2.3%.

Papers led
54
2021–2025
Trials led
11
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 6620212022: 131320222023: 9920232024: 181820242025: 882025

5 hospitals in Nanning for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07459296

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical UniversityNanning

  2. Recruiting
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05892354

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 13 listed hospitals as study sitesFuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Liuzhou, Nanchang, Nanning, Wuzhou

  3. Not yet recruiting
    Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07303283

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical UniversityNanning

  4. Not yet recruiting
    Impacted Tooth Management and Osteoradionecrosis Risk in NPC
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07764887

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuilin, Liuzhou, Nanning, Wuzhou, Zhongshan

  5. Not yet recruiting
    Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06680115

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical UniversityNanning

  6. Recruiting
    IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT05941741

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Nanchang, Nanning

  7. Recruiting
    Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06445088

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuzhou, Zhongshan

  8. Recruiting
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    Phase
    Phase 3
    Started
    2022-04
    Registry
    NCT05340491

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  9. Recruiting
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    Phase
    Phase 3
    Started
    2020-03
    Registry
    NCT03907826

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueImaging & AIRecurrent / metastatic disease
Departments in papersRadiation oncologyPathology / laboratory medicineENT / head & neck surgeryRadiology / nuclear medicine
Papers it led54
  1. BHLHE40-mediated upregulation of CAV1 decreases the radiosensitivity of nasopharyngeal carcinoma.2025American journal of physiology. Cell physiology
  2. Muscle-specific MRI grading of soft tissue involvement provides additional prognostic value beyond skull base criteria in nasopharyngeal carcinoma: a retrospective study.2025BMC cancerFree full text
  3. Clinical features and CTA imaging of radiation-induced carotid pseudoaneurysms in nasopharyngeal carcinoma.2025BMC medical imagingFree full text
  4. Baseline audiometric assessment of newly diagnosed nasopharyngeal carcinoma patients: a multicentre cross-sectional study.2025International journal of cancer
  5. Radiomics based on dual-energy CT for noninvasive prediction of cervical lymph node metastases in patients with nasopharyngeal carcinoma.2025Radiography (London, England : 1995)
  6. The potential value of IVIM MR for radiation-related hypothyroidism in nasopharyngeal carcinoma.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  7. Effect of HSPA 8 on the biological function of NPC cells and its mechanism.2025Scientific reportsFree full text
  8. Carboxylesterase 4A Inhibits the Malignant Biological Behavior of Nasopharyngeal Carcinoma via the PI3K/AKT Pathway.2025Technology in cancer research & treatmentFree full text
  9. Oncogenic and immunological roles of RACGAP1 in pan-cancer and its potential value in nasopharyngeal carcinoma.2024Apoptosis : an international journal on programmed cell death
  10. Establishment of a visualized mouse orthotopic xenograft model of nasopharyngeal carcinoma.2024Cancer biology & therapyFree full text
  11. Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  12. Immune checkpoint inhibitor combined with chemotherapy versus chemotherapy alone in the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis of random controlled trials.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  13. Circulating tumor cells: a valuable indicator for locally advanced nasopharyngeal carcinoma.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  14. Prediction of severe radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma using the combined systemic immune-inflammatory index and prognostic nutritional index.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  15. The prognostic implications of radiologic extranodal extension in the lymph nodes of patients with nasopharyngeal cancer.2024Future oncology (London, England)Free full text
  16. Prognostic value of sarcopenia in the patients with locally advanced nasopharyngeal carcinoma.2024Japanese journal of radiology
  17. New T staging recommendations for recurrent nasopharyngeal carcinoma.2024Journal of cancer research and clinical oncologyFree full text
  18. Study on carotid artery stenosis after radiotherapy for nasopharyngeal carcinoma.2024Journal of cancer research and clinical oncologyFree full text
  19. Effects of concurrent chemoradiotherapy with or without Endostar on the regression of retropharyngeal lymph node and prognosis of patients with locally advanced nasopharyngeal carcinoma: a retrospective study.2024Journal of cancer research and clinical oncologyFree full text
  20. LncRNA HOTAIRM1 promotes radioresistance in nasopharyngeal carcinoma by modulating FTO acetylation-dependent alternative splicing of CD44.2024Neoplasia (New York, N.Y.)Free full text
  21. Quantitative parameter analysis of pretreatment dual-energy computed tomography in nasopharyngeal carcinoma cervical lymph node characteristics and prediction of radiotherapy sensitivity.2024Radiation oncology (London, England)Free full text
  22. Potential predictive value of IVIM MR for xerostomia in nasopharyngeal carcinoma.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  23. The feasibility of level Ib-sparing intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma and high-risk factors classified based on the International Guideline.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  24. Combined pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts survival and prognosis in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.2024Scientific reportsFree full text
  25. Effect of modified Baduanjin exercise on nutritional status in patients with nasopharyngeal carcinoma: a randomized controlled trial.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  26. Risk factors and the nomogram model for malnutrition in patients with nasopharyngeal carcinoma.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  27. Taxonomy and anticancer potential of Streptomyces niphimycinicus sp. nov. against nasopharyngeal carcinoma cells.2023Applied microbiology and biotechnology
  28. Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.2023BMC cancerFree full text
  29. Nomogram to Predict Long-Term Overall Survival and Cancer-Specific Survival of Radiotherapy Patients with Nasopharyngeal Carcinoma.2023BioMed research internationalFree full text
  30. Scheduling radiotherapy for patients with nasopharyngeal carcinoma in the corresponding time window can reduce radiation-induced oral mucositis: A randomized, prospective study.2023Cancer medicineRCTFree full text
  31. WDHD1 is over-expressed in nasopharyngeal carcinoma and may control the expression of ITGAV.2023FEBS open bioFree full text
  32. Exploring the expression of SNHG1 and its effect on the PI3K-AKT axis in nasopharyngeal cancer.2023Neoplasma
  33. Quality evaluation index development for nutritional management in patients with nasopharyngeal carcinoma during peri-radiotherapy.2023Nutrition (Burbank, Los Angeles County, Calif.)
  34. The application of the PDCA cycle in the nutritional management of patients with nasopharyngeal carcinoma.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  35. Performance of Pretreatment MRI-Based Radiomics in Recombinant Human Endostatin Plus Concurrent Chemoradiotherapy Response Prediction in Nasopharyngeal Carcinoma: A Retrospective Study.2023Technology in cancer research & treatmentFree full text
  36. Analysis of the risk of death and clinical management for nasal or nasopharyngeal bleeding occurring after radiotherapy for nasopharyngeal carcinoma.2022Auris, nasus, larynx
  37. Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis.2022BMC cancerFree full text
  38. Clinical value and potential mechanisms of BUB1B up-regulation in nasopharyngeal carcinoma.2022BMC medical genomicsFree full text
  39. Development and validation of an MRI-based radiomic model for predicting overall survival in nasopharyngeal carcinoma patients with local residual tumors after intensity-modulated radiotherapy.2022BMC medical imagingFree full text
  40. Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial.2022CancerRCT
  41. Nomogram Based on Clinical and Radiomics Data for Predicting Radiation-induced Temporal Lobe Injury in Patients with Non-metastatic Stage T4 Nasopharyngeal Carcinoma.2022Clinical oncology (Royal College of Radiologists (Great Britain))
  42. Potential Molecular Mechanism of Upregulated Aryl Hydrocarbon Receptor Nuclear Translocator 2 in Nasopharyngeal Carcinoma.2022Computational and mathematical methods in medicineFree full text
  43. Predicting Nomogram for Severe Oral Mucositis in Patients with Nasopharyngeal Carcinoma during Intensity-Modulated Radiation Therapy: A Retrospective Cohort Study.2022Current oncology (Toronto, Ont.)Free full text
  44. Downregulation of MicroRNA-1 and Its Potential Molecular Mechanism in Nasopharyngeal Cancer: An Investigation Combined with In Silico and In-House Immunohistochemistry Validation.2022Disease markersFree full text
  45. Downregulated miR-150-5p in the Tissue of Nasopharyngeal Carcinoma.2022Genetics researchFree full text
  46. FOXM1 regulates glycolysis in nasopharyngeal carcinoma cells through PDK1.2022Journal of cellular and molecular medicineFree full text
  47. Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study.2022Radiation oncology (London, England)Free full text
  48. Prognostic value of the cervical lymph node necrosis ratio in nasopharyngeal carcinoma.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  49. Long-term efficacy and adverse reactions of IMRT combined with Endostar versus IMRT combined with chemotherapy for locally advanced nasopharyngeal carcinoma: a retrospective study.2021Annals of palliative medicine
  50. Tubulin polymerization promoting protein family member 3 (TPPP3) overexpression inhibits cell proliferation and invasion in nasopharyngeal carcinoma.2021BioengineeredFree full text
  51. Human/eukaryotic ribosomal protein L14 (RPL14/eL14) overexpression represses proliferation, migration, invasion and EMT process in nasopharyngeal carcinoma.2021BioengineeredFree full text
  52. miRNAs derived from circulating small extracellular vesicles as diagnostic biomarkers for nasopharyngeal carcinoma.2021Cancer scienceFree full text
  53. Radiation Therapy-Induced Changes of the Nasopharyngeal Commensal Microbiome in Nasopharyngeal Carcinoma Patients.2021International journal of radiation oncology, biology, physics
  54. Prognostic nomogram to predict the distant metastasis after intensity-modulated radiation therapy for patients with nasopharyngeal carcinoma.2021MedicineFree full text
All its trials on ClinicalTrials.gov, any status22
  1. Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCRecruitingNCT07459296Lead sponsorPhase 3Start 2026-03
  2. Impacted Tooth Management and Osteoradionecrosis Risk in NPCNot yet recruitingNCT07764887Lead sponsorN/AStart 2026-08
  3. Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal CarcinomaNot yet recruitingNCT06680115Lead sponsorPhase 2Start 2024-11
  4. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After ChemoradiotherapyRecruitingNCT05892354Lead sponsorN/AStart 2023-06
  5. Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT02907710Lead sponsorPhase 3Start 2016-10
  6. Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal CarcinomaCompletedNCT02237924Lead sponsorPhase 2Start 2014-09
  7. Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal CarcinomaNot yet recruitingNCT07303283Lead (inferred)Phase 2Start 2026-09
  8. Hearing Impairment of Nasopharyngeal CarcinomaCompletedNCT05330169Lead (inferred)Start 2022-09
  9. PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT05340270Lead (inferred)Phase 2Start 2022-07
  10. Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal CarcinomaCompletedNCT04004871Lead (inferred)Phase 2Start 2019-03
  11. A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT01479504Lead (inferred)Phase 3Start 2011-11
  12. Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal CarcinomaRecruitingNCT06445088Study siteStart 2024-05
  13. IC Plus Low-dose Radiation Plus Cadonilimab in LANPCRecruitingNCT05941741Study sitePhase 3Start 2024-01
  14. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Study sitePhase 3Start 2022-04
  15. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Study sitePhase 3Start 2020-03
  16. Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06712888Study sitePhase 3Start 2025-02
  17. Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal CarcinomaActive, not recruitingNCT05780372Study sitePhase 3Start 2023-08
  18. Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal CarcinomaActive, not recruitingNCT05979961Study sitePhase 3Start 2023-09
  19. Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic ImagesStatus unknownNCT05627310Study siteStart 2022-11
  20. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  21. Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid StenosisSuspendedNCT02022293Study sitePhase 2Start 2017-01
  22. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal CancerStatus unknownNCT01074021Study sitePhase 3Start 2009-10
More papers found outside PubMed (not counted)56
  1. 1393P MiPEP133 promoting radiosensitivity of nasopharyngeal carcinoma via downregulation of ACL-mediated DNA break2025Annals of Oncologyarticle
  2. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncologyarticle
  3. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  4. Additional file 1 of Muscle-specific MRI grading of soft tissue involvement provides additional prognostic value beyond skull base criteria in nasopharyngeal carcinoma: a retrospective study2025Figsharearticle
  5. CACA guidelines for holistic integrative management of adolescent and childhood nasopharyngeal carcinoma2025Holistic Integrative Oncologyarticle
  6. Induction chemotherapy with or without toripalimab followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter, open-label, randomized, controlled, phase 2 trial.2025Journal of Clinical Oncologyconference-abstract
  7. Muscle-specific MRI grading of soft tissue involvement provides additional prognostic value beyond skull base criteria in nasopharyngeal carcinoma: a retrospective study2025Figsharesupplementary-materials
  8. The Impact of Air Cavity Correction on Optimization Convergence Error in Intensity-Modulated Radiation Therapy Planning for Nasopharyngeal Carcinoma2025ScienceDBdataset
  9. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncologyconference-abstract
  10. Acetyl-CoA acyltransferase 1 is a potential tumor suppressor gene associated with immune cell infiltration in nasopharyngeal carcinoma2024Research Squarepreprint
  11. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.2024Journal of Clinical Oncologyconference-abstract
  12. Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial.2024Journal of Clinical Oncologyconference-abstract
  13. Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial.2024Journal of Clinical Oncologyconference-abstract
  14. Predicting the risk of sarcopenia in Nasopharyngeal Carcinoma patients: Development and assessment of a new predictive nomogram2024Research Squarepreprint
  15. Prognostic Analysis of Nonmetastatic Nasopharyngeal Carcinoma in Older Patients Undergoing Intensity‐Modulated Radiotherapy2024International Journal of Clinical Practicearticle
  16. Additional file 1 of Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway2023Figsharedataset
  17. Additional file 3 of Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway2023Figsharedataset
  18. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncologyarticle
  19. Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.2023Journal of Clinical Oncologyconference-abstract
  20. Efficacy and safety of immunonutrition in preventing oral mucositis during concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.2023Journal of Clinical Oncologyconference-abstract
  21. Exploring the Clinical Characteristics and Survival of Early-Onset and Late-Onset Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  22. Icariside II targets in vitro MAPK and PI3K/Akt signaling in human nasopharyngeal carcinoma cells to induce apoptotic death and suppress proliferation2023Research Squarepreprint
  23. Impact of radiotherapy for nasopharyngeal carcinoma on carotid stenosis risk: a meta-analysis2023Figsharedataset
  24. Perspective Chapter: Modulation of Latent to Lytic Cycle Infection Switch and Its Implication in EBV Mediated Tumorigenicity2023IntechOpen eBooksbook-chapter
  25. Potential Predictive Value of Intravoxel Incoherent Motion Magnetic Resonance for Xerostomia of Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  26. Surgical treatment of oligometastatic nasopharyngeal carcinoma2023Clinical Surgical Oncologyarticle
  27. The Feasibility of Level Ib Sparing Intensity Modulated Radiation Therapy in Nasopharyngeal Carcinoma Patients with High-Risk Factors: Based on International Guideline2023International Journal of Radiation Oncology*Biology*Physicsarticle
  28. WITHDRAWN: Effect of modified Baduanjin exercise on nutritional status in patients with nasopharyngeal carcinoma: A randomized controlled trial2023Research Squarepreprint
  29. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset
  30. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  31. Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis2022Figsharereview
  32. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  33. Additional file 2 of Development and validation of an MRI-based radiomic model for predicting overall survival in nasopharyngeal carcinoma patients with local residual tumors after intensity-modulated radiotherapy2022Figsharedataset
  34. Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma2022Figsharedataset
  35. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  36. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  37. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  38. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  39. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  40. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  41. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  42. Analysis of hnRNP K Expression and Relevance for Clinical Outcomes in Hepatocellular carcinoma2022Research Squarepreprint
  43. Establishment of a visualized mouse orthotopic model of nasopharyngeal carcinoma.2022Journal of Clinical Oncologyconference-abstract
  44. Factors influencing out of pocket ratio to CPS among NPC patients in Guangxi: 2014-20202022IEEE International Conference on High Performance Computing and Communications; IEEE International Conference on Smart City; IEEE International Conference on Data Science and Systems (HPCC/SmartCity/DSS)conference-paper
  45. Myocardin immunohistochemistry index is associated with clinical prognosis in nasopharyngeal carcinoma: a clinical practice-based cohort study2022Tropical Journal of Pharmaceutical Researcharticle
  46. Recombinant human endostatin combined with intensity-modulated radiotherapy in low-risk locoregionally advanced nasopharyngeal carcinoma: A phase II, randomized, multicenter clinical trial.2022Journal of Clinical Oncologyconference-abstract
  47. The performance of pretreatment MR-based radiomics in Recombinant human endostatin plus concurrent chemoradiotherapy response prediction in nasopharyngeal carcinoma: A primary study2022Research Squarepreprint
  48. Upregulation of ITGAV and the underlying mechanisms in nasopharyngeal carcinoma2022Electronic Journal of Biotechnologyarticle
  49. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncologyarticle
  50. Cucurbitacin B as a Chinese Medicine Monomer Inhibits Cell Proliferation, Invasion, and Migration in Nasopharyngeal Carcinoma2021Journal of Nanomaterialsarticle
  51. Diagnosis and Therapy of Nasopharyngeal Carcinoma2021IntechOpen eBooksbook-chapter
  52. Endostar combined with intensity-modulated radiotherapy in low-risk local advanced nasopharyngeal carcinoma: A phase II, randomized, multicentric clinical trial.2021Journal of Clinical Oncologyconference-abstract
  53. Genome-Scale CRISPR-Cas9 Knockout Screening in Nasopharyngeal Carcinoma for Radiosensitive and Radioresistant Genes2021International Journal of Radiation Oncology*Biology*Physicsarticle
  54. Is the Equivalent Uniform Dose Model Being Used Properly? Impact of Dose Distribution on Parameter and Predictive Ability2021International Journal of Radiation Oncology*Biology*Physicsarticle
  55. Maintenance intervention to improve survival in patients with metastatic nasopharyngeal carcinoma who benefit from first-line treatment: A prospective multicenter randomized controlled clinical study.2021Journal of Clinical Oncologyconference-abstract
  56. Potential Role of The Upregulation of The Zinc Finger Protein of The Cerebellum 2 In Nasopharyngeal Carcinoma2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 112025

4 hospitals in Nanning for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomics
Departments in papersMedical oncologyPathology / laboratory medicine
Papers it led4
  1. Macrophage Infiltration and ITGB2 Expression in ESCC: A Novel Correlation.2025Cancer medicineFree full text
  2. Comprehensive analysis of clinical features, mRNA splicing, and immunological role of REEP5 in esophageal squamous cell carcinoma.2024Scientific reportsFree full text
  3. Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis.2021BMC cancerFree full text
  4. Overexpression of cyclin-dependent kinase 1 in esophageal squamous cell carcinoma and its clinical significance.2021FEBS open bioFree full text
More papers found outside PubMed (not counted)12
  1. Research on the Expression and Mechanism of LRRC8D in Esophageal Squamous Cell Carcinoma2025Research Squarepreprint
  2. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  3. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  4. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  6. Exosomal circRNA FNDC3B promotes the progression of esophageal squamous cell carcinoma by sponging miR-490-5p and regulating thioredoxin reductase 1 expression2022Figsharedataset
  7. Significance of Sarcopenia and the Neutrophil-to-Lymphocyte Ratio in Elderly Patients with Esophageal Squamous Cell Carcinoma2022Book Publisher International (a part of SCIENCEDOMAIN International)book-chapter
  8. The Clinical Significance of Forkhead Box M1 in Esophageal Squamous Cell Carcinoma Tissues: A Study Based on In-house Immunohistochemistry, RNA-sequencing, and Data Mining2022Research Squarepreprint
  9. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset
  10. Long non-coding RNA BCAR4 aggravated proliferation and migration in esophageal squamous cell carcinoma by negatively regulating p53/p21 signaling pathway2021Figsharedataset
  11. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figsharedataset
  12. Overexpression of UBE2C in Esophageal Squamous Cell Carcinoma Tissues and Molecular Analysis2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 134 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
134
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 181820212022: 232320222023: 252520232024: 181820242025: 46462025

5 hospitals in Nanning for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2026-04
    Registry
    NCT07478302

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Nanning

  2. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

  3. Not yet recruiting
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07724951

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai

  4. Not yet recruiting
    TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07350070

    Age 18 years to 75 years (registered criteria)

    Led by Tongji Hospital; 4 listed hospitals as study sitesFuzhou, Jinan, Nanning, Qingdao, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionSurgery & liver transplant
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicineMedical oncology
Papers it led134
  1. Incorporating new criteria can improve the ability of CEUS LI-RADS to differentiate HCC from non-HCC malignancies.2026Abdominal radiology (New York)
  2. NSUN3-Mediated ROS Accumulation Promotes Hepatocellular Carcinoma Proliferation and Activates PI3K/AKT Pathway.2026Biochemical genetics
  3. Time-dependent diffusion-weighted MRI discriminates hepatocellular carcinoma from intrahepatic cholangiocarcinoma: A prospective animal model study.2026Magnetic resonance imaging
  4. Time-dependent diffusion MRI combined with enhanced MRI and clinical indicators for preoperative prediction of CK19 expression status in hepatocellular carcinoma: a prospective study.2026Magnetic resonance imaging
  5. A Phototherapy Nanosensitizer-Unlocked Multihit Strategy to Inhibit Tumor Stemness and Potentiate Sorafenib Response in Hepatocellular Carcinoma.2025ACS applied materials & interfaces
  6. Development of a model combining CEUS LI-RADS and clinical features for predicting glypican-3 expression in hepatocellular carcinoma.2025Abdominal radiology (New York)
  7. Development and validation of a combined radiomic and clinical model based on contrast-enhanced ultrasound for preoperative prediction of CK19-positive hepatocellular carcinoma.2025Abdominal radiology (New York)
  8. Radiomics-based Machine Learning for Predicting Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2025Academic radiology
  9. An analysis of the clinical significance of the TKI-resistant gene ZNF687 for hepatocellular carcinoma patients.2025Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  10. Predictive value of intra-hepatectomy ICGR15 of the remnant liver for post-hepatectomy liver failure in hemi-hepatectomy: a prospective study.2025BMC cancerFree full text
  11. Donafenib activates the p53 signaling pathway in hepatocellular carcinoma, induces ferroptosis, and enhances cell apoptosis.2025Clinical and experimental medicineFree full text
  12. Silencing NCAPD3 Inhibits Tumor Growth and Metastasis in Hepatocellular Carcinoma by Suppressing PI3K-AKT Signalling Pathway.2025Current medical science
  13. Novel biomarker in hepatocellular carcinoma: Stearoyl-CoA desaturase 1.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  14. HBV-induced N6 methyladenosine modification of PARP1 enhanced AFB1-related DNA damage and synergistically contribute to HCC.2025Ecotoxicology and environmental safety
  15. Multimodal analysis reveals potential association of CDH13 with endothelial cells and its overexpression in hepatocellular carcinoma.2025European journal of medical researchFree full text
  16. A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1/PRDX1 as therapeutic targets.2025Frontiers in immunologyFree full text
  17. Stereotactic body radiation therapy combined with cadonilimab and lenvatinib in the treatment of hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombus: a prospective, multicenter, single-arm, phase II clinical trial.2025Frontiers in immunologyFree full text
  18. The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.2025Frontiers in immunologyFree full text
  19. Potential regulatory mechanism of overexpression of phosphatidylinositol glycan anchor biosynthesis class U on the glycolytic pathway in hepatocellular carcinoma.2025Gene
  20. FAHD1-mediated pyruvate metabolism in hepatocellular carcinoma: Multi-omics and causal genetic evidence.2025HGG advancesFree full text
  21. Structural characterization and functional role of SLC7A6 in GSSG transport and Ferroptosis regulation.2025International journal of biological macromolecules
  22. Serum Alpha-Fetoprotein-Tumor Size Ratio as a Prognostic Marker After Hepatic Resection for Primary Hepatocellular Carcinoma: Propensity Score Matched Retrospective Cohort Study.2025JMIR cancerFree full text
  23. Development and Validation of an Extra Spindle Pole Bodies-like 1-Based Diagnostic and Prognostic Model for Hepatitis B Virus-Related Hepatocellular Carcinoma: Retrospective Cohort Study.2025JMIR medical informaticsFree full text
  24. Impact of pre-examination video education in Gd-EOB-DTPA-enhanced liver MRI: A comparative study.2025Journal of medical radiation sciencesFree full text
  25. Hsa_circ_0016662 acts as a prognostic biomarker and promotes the progression of hepatocellular carcinoma via autophagy regulation.2025Journal of translational medicineFree full text
  26. Proteomic and metabolomic analysis of platelet related samples reveals energy metabolism disorders in hepatocellular carcinoma.2025Journal of translational medicineFree full text
  27. AP5Z1 affects hepatocellular carcinoma growth and autophagy by regulating PTEN ubiquitination and modulating the PI3K/Akt/mTOR pathway.2025Journal of translational medicineFree full text
  28. Integrating single-cell and bulk RNA sequencing data to characterize the heterogeneity of glycan-lipid metabolism polarization in hepatocellular carcinoma.2025Journal of translational medicineFree full text
  29. Spleen volume after stage-I associated liver partition and portal vein ligation for staged hepatectomy predicts future liver remnant.2025Langenbeck's archives of surgeryFree full text
  30. MRI-Based Topology Deep Learning Model for Noninvasive Prediction of Microvascular Invasion and Assisting Prognostic Stratification in HCC.2025Liver international : official journal of the International Association for the Study of the LiverFree full text
  31. Transformer model based on Sonazoid contrast-enhanced ultrasound for microvascular invasion prediction in hepatocellular carcinoma.2025Medical physics
  32. Balancing Image Quality and Iodine Intake: Insights from CT Spectral Imaging of the Portal Vein.2025Medical science monitor : international medical journal of experimental and clinical researchFree full text
  33. Deubiquitinase-associated mRNA signature model predicts prognosis and influences the immune microenvironment in patients with hepatocellular carcinoma: An observational study.2025MedicineFree full text
  34. Overexpression of PLK1 Molecule Following Incomplete Thermal Ablation Promotes the Proliferation and Invasion of Residual Hepatocellular Carcinoma.2025Molecular biotechnology
  35. Heterogeneity of tumor-associated neutrophils in hepatocellular carcinoma.2025Molecular immunology
  36. Nitidine chloride inhibits the progression of hepatocellular carcinoma by suppressing IGF2BP3 and modulates metabolic pathways in an m6A-dependent manner.2025Molecular medicine (Cambridge, Mass.)Free full text
  37. METTL3/IGF2BP2 stabilizes IQGAP3 via m6A modification to drive HCC metastasis through TGF-β/Smad signaling and EMT.2025Pathology, research and practice
  38. Exploring the level of metabolic reprogramming and the role of prognostic factor SF3A3 in hepatocellular carcinoma through integrated single-cell landscape analysis.2025PloS oneFree full text
  39. Epigallocatechin Gallate Derivative Y6 Reverses Oxaliplatin Resistance in Hepatocellular Carcinoma via Targeting the MiR-338-3p/HIF-1α/TWIST Axis to Inhibit EMT.2025Recent patents on anti-cancer drug discovery
  40. EXOSC3 knockdown induces G1/S phase arrest to suppress hepatocellular carcinoma cell proliferation.2025Scientific reportsFree full text
  41. Atorvastatin negatively regulates MAPK pathway in vitro to inhibit proliferation, migration, and invasion of hepatocellular carcinoma cells.2025Scientific reportsFree full text
  42. Fatty acid-binding proteins as potential biomarkers for human cancer prognosis.2025Scientific reportsFree full text
  43. Exploreing the potential mechanism of Aitongxiao formula inhibiting hepatocellular carcinoma in vitro and in vivo based on network Pharmacology.2025Scientific reportsFree full text
  44. Cystathionine gamma-lyase as an inflammatory factor and its link with immune inflammation in hepatitis B virus-related liver disease.2025Scientific reportsFree full text
  45. The LncRNA lnc-POTEM-4:14 promotes HCC progression by interacting with FOXK1.2025Scientific reportsFree full text
  46. Comprehensive Pan-Cancer Analysis and Functional Studies Reveal SLC2A6 as a Ferroptosis Modulator in Hepatocellular carcinoma.2025Scientific reportsFree full text
  47. Liver resection in stage 0-A HCC in segments 7/8: a propensity-matched analysis comparing open, laparoscopic, and robotic approach.2025Surgical endoscopyFree full text
  48. 2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione from Averrhoa carambola L. roots: Suppressing hepatocellular carcinoma progression through ROS accumulation and p53 pathway-mediated apoptosis.2025Toxicology and applied pharmacology
  49. Diagnostic performance of serum origin recognition complex subunit 1 protein for hepatitis B virus-related hepatocellular carcinoma.2025World journal of gastroenterologyFree full text
  50. Robotic versus open hepatectomy for large(≥ 5 cm) hepatocellular carcinoma: A large volume center, propensity score matched study.2025World journal of surgical oncologyFree full text
  51. Intra-individual comparison of Sonazoid contrast-enhanced ultrasound and SonoVue contrast-enhanced ultrasound in diagnosing hepatocellular carcinoma.2024Abdominal radiology (New York)
  52. Role of CCR1/5/7 in hepatocellular carcinoma: a study on prognostic evaluation, molecular subtyping, and association with immune infiltration.2024AgingFree full text
  53. RBCK1 overexpression is associated with immune cell infiltration and poor prognosis in hepatocellular carcinoma.2024AgingFree full text
  54. Prediction of prognosis of patients with hepatocellular carcinoma based on immune-related score.2024Asian journal of surgery
  55. M2 tumor-associated macrophages and CXCL2 induce lipid remodeling in hepatocellular carcinoma cell lines.2024Biomedical chromatography : BMC
  56. Prognostic value of geriatric nutritional risk index and prognostic nutritional index in hepatocellular carcinoma.2024Clinical nutrition ESPEN
  57. Value of the Stretched Exponential and Fractional-order Model in Differentiating Hepatocellular from Intrahepatic Cholangiocarcinoma.2024Current medical imaging
  58. Potential Value of the Stretched Exponential and Fractional Order Calculus Model in Discriminating Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: An Animal Experiment of Orthotopic Xenograft Nude Mice.2024Current medical imaging
  59. Exploring the impact of insufficient thermal ablation on hepatocellular carcinoma: NDST2 overexpression mechanism and its role in facilitating growth and invasion of residual cancer cells.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  60. A Novel Prognostic Model of Hepatocellular Carcinoma per Two NAD+ Metabolic Synthesis-Associated Genes.2024International journal of molecular sciencesFree full text
  61. The Value of CEUS LI-RADS combined with AFP in early diagnosis of hepatocellular carcinoma in low- and high-risk patients.2024Journal of cancer research and therapeutics
  62. Clinical Significance of Upregulation of EZH1 Expression in Hepatocellular Carcinoma Tissues.2024Journal of gastrointestinal and liver diseases : JGLD
  63. Letter to Dr. Wang Jian and his team about our paper "Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study" published on "La radiologi2024La Radiologia medica
  64. Identification and validation of ATP6V1G1-regulated phosphorylated proteins in hepatocellular carcinoma.2024PloS oneFree full text
  65. Nomogram based on the neutrophil-to-lymphocyte ratio and MR diffusion quantitative parameters for predicting Ki67 expression in hepatocellular carcinoma from a prospective study.2024Scientific reportsFree full text
  66. Analysis of clinicopathologic and imaging features of dual-phenotype hepatocellular carcinoma.2024Scientific reportsFree full text
  67. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.2024Scientific reportsFree full text
  68. CEUS LI-RADS in Combination With the Serum Biomarker-Based ASAP Model Improves the Diagnostic Performance of HCC in High-Risk Patients.2024Ultrasound in medicine & biology
  69. Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies.2023Abdominal radiology (New York)
  70. SART3, regulated by p53, is a biomarker for diagnosis, prognosis and immune infiltration in hepatocellular carcinoma.2023AgingFree full text
  71. Correlation Between Serum ESPL1 and Hepatitis B Virus-related Hepatocellular Carcinoma Histological Grade: A Chinese Single-center Case-control Study.2023Anticancer research
  72. Differences between CEUS LI-RADS and CECT LI-RADS in the diagnosis of focal liver lesions in patients at risk for HCC.2023BMC medical imagingFree full text
  73. Development and validation of a nomogram for survival prediction in hepatocellular carcinoma after partial hepatectomy.2023BMC surgeryFree full text
  74. The investigation on the hypercoagulability of hepatocellular carcinoma-related cerebral infarction with thromboelastography.2023Brain and behaviorFree full text
  75. Advances in SEMA3F regulation of clinically high-incidence cancers.2023Cancer biomarkers : section A of Disease markersFree full text
  76. Clinical Implication of E2F Transcription Factor 1 in Hepatocellular Carcinoma Tissues.2023Cancer biotherapy & radiopharmaceuticals
  77. Highly expressed carbohydrate sulfotransferase 11 correlates with unfavorable prognosis and immune evasion of hepatocellular carcinoma.2023Cancer medicineFree full text
  78. Nucleoporin 107 is a prognostic biomarker in hepatocellular carcinoma associated with immune infiltration.2023Cancer medicineFree full text
  79. A Retrospective Study of Long-Term Clinical Outcomes in Patients with Chronic Hepatitis C Treated with Interferon and Ribavirin.2023Discovery medicine
  80. Case report: hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib for conversion therapy of colorectal cancer liver metastases.2023Frontiers in immunologyFree full text
  81. 4-Methoxydalbergione Elicits Anticancer Effects by Upregulation of GADD45G in Human Liver Cancer Cells.2023Journal of healthcare engineeringFree full text
  82. Proteomics profiling of nontumor liver tissues identifies prognostic biomarkers in hepatitis B-related hepatocellular carcinoma.2023Journal of medical virology
  83. Comparison of the Feasibility and Diagnostic Performance of ACR CEUS LI-RADS and a Modified CEUS LI-RADS for HCC in Examinations Using Sonazoid.2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  84. Can Modifications of LR-M Criteria Improve the Diagnostic Performance of Contrast-Enhanced Ultrasound LI-RADS for Small Hepatic Lesions up to 3 cm?2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  85. Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study.2023La Radiologia medicaRCTFree full text
  86. Pre-operative MRI features predict early post-operative recurrence of hepatocellular carcinoma with different degrees of pathological differentiation.2023La Radiologia medicaFree full text
  87. Prognostic value and potential molecular mechanism of ITGB superfamily members in hepatocellular carcinoma.2023MedicineFree full text
  88. High expression of ENPP2 is an independent predictor of poor prognosis in liver cancer.2023MedicineFree full text
  89. Nomogram to predict the prognosis of patients with AFP-negative hepatocellular carcinoma undergoing chemotherapy: A SEER based study.2023MedicineFree full text
  90. A radiomics model based on magnetic resonance imaging to predict cytokeratin 7/19 expression and liver fluke infection of hepatocellular carcinoma.2023Scientific reportsFree full text
  91. Robust analysis of a novel PANoptosis-related prognostic gene signature model for hepatocellular carcinoma immune infiltration and therapeutic response.2023Scientific reportsFree full text
  92. Outer dynein arm docking complex subunit 2 polymorphism rs7893462 modulates hepatocellular carcinoma susceptibility and can serve as an overall survival biomarker for hepatitis B virus-related hepatocellular carcinoma after hepatectomy: a c2023World journal of surgical oncologyFree full text
  93. Identify GADD45G as a potential target of 4-methoxydalbergione in treatment of liver cancer: bioinformatics analysis and in vivo experiment.2023World journal of surgical oncologyFree full text
  94. Gd-EOB-DTPA-enhanced magnetic resonance imaging may help identify patients with hepatocellular carcinoma eligible for treatment targeted at RAF1.2022Abdominal radiology (New York)
  95. Diagnostic performance and interreader agreement of CEUS LI-RADS in ≤ 30 mm liver nodules with different experienced radiologists.2022Abdominal radiology (New York)
  96. Gender disparity in hepatocellular carcinoma recurrence after curative hepatectomy.2022Annals of hepatology
  97. The expression characteristics and clinical significance of ACP6, a potential target of nitidine chloride, in hepatocellular carcinoma.2022BMC cancerFree full text
  98. Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma.2022BMC gastroenterologyFree full text
  99. Bioinformatics Analysis for Constructing a Six-Immune-Related Long Noncoding RNA Signature as a Prognostic Model of Hepatocellular Carcinoma.2022BioMed research internationalFree full text
  100. Long non-coding RNA LINC01793 as a potential diagnostic biomarker of hepatitis B virus-related hepatocellular carcinoma.2022Clinical biochemistry
  101. Diagnostic value of long noncoding RNA LINC01485 in patients with colorectal cancer.2022Clinical biochemistry
  102. Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma.2022European journal of radiology
  103. PSMB5 overexpression is correlated with tumor proliferation and poor prognosis in hepatocellular carcinoma.2022FEBS open bioFree full text
  104. A cohesin-associated gene score may predict immune checkpoint blockade in hepatocellular carcinoma.2022FEBS open bioFree full text
  105. Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis.2022Frontiers in endocrinologyFree full text
  106. A novel Peng's test in reducing bile leakage after partial hepatectomy for hepatocellular carcinoma: From an animal study to a clinical cohort Propensity score matching comparative study.2022International journal of surgery (London, England)
  107. UBR7 inhibits HCC tumorigenesis by targeting Keap1/Nrf2/Bach1/HK2 and glycolysis.2022Journal of experimental & clinical cancer research : CRFree full text
  108. EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinoma.2022Journal of hepatology
  109. Multimodal imaging in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus.2022Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
  110. Construction of a 3-mRNA hypoxia prognostic model to evaluate immune microenvironment in hepatocellular carcinoma.2022MedicineFree full text
  111. Gene mining of immune microenvironment in hepatocellular carcinoma.2022MedicineFree full text
  112. Bioinformatics analysis and experimental verification of five metabolism-related lncRNAs as prognostic models for hepatocellular carcinoma.2022MedicineFree full text
  113. Expression of IER3 in hepatocellular carcinoma: clinicopathology, prognosis, and potential regulatory pathways.2022PeerJFree full text
  114. Testis-specific protein Y-encoded 1 regulates androgen receptor expression through the MAPK/ERK pathway in male hepatocellular carcinoma.2022Saudi medical journalFree full text
  115. Radiomics and nomogram of magnetic resonance imaging for preoperative prediction of microvascular invasion in small hepatocellular carcinoma.2022World journal of gastroenterologyFree full text
  116. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.2022World journal of surgical oncologyFree full text
  117. Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt.2021Abdominal radiology (New York)
  118. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.2021BMC cancerFree full text
  119. Effect of timing of surgical resection of primary hepatocellular carcinoma on survival outcomes in elderly patients and prediction of clinical models.2021BMC gastroenterologyFree full text
  120. Hypomethylation-driven overexpression of HJURP promotes progression of hepatocellular carcinoma and is associated with poor prognosis.2021Biochemical and biophysical research communications
  121. Expression, prognosis value, and immune infiltration of lncRNA ASB16-AS1 identified by pan-cancer analysis.2021BioengineeredFree full text
  122. Clinical significance and molecular mechanism of angiotensin-converting enzyme 2 in hepatocellular carcinoma tissues.2021BioengineeredFree full text
  123. Integrated multi-omics analysis of the clinical relevance and potential regulatory mechanisms of splicing factors in hepatocellular carcinoma.2021BioengineeredFree full text
  124. Down-regulation of microRNA-125b-2-3p is a risk factor for a poor prognosis in hepatocellular carcinoma.2021BioengineeredFree full text
  125. Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular Carcinoma.2021BioengineeredFree full text
  126. Preoperative combi-elastography for the prediction of early recurrence after curative resection of hepatocellular carcinoma.2021Clinical imagingRCT
  127. DNA Damage Repair Profiles Alteration Characterize a Hepatocellular Carcinoma Subtype With Unique Molecular and Clinicopathologic Features.2021Frontiers in immunologyFree full text
  128. LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3.2021Journal of experimental & clinical cancer research : CRFree full text
  129. Hepatic Arterioportal Fistula Is Associated with Decreased Future Liver Remnant Regeneration after Stage-I ALPPS for Hepatocellular Carcinoma.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  130. Expression of Cell Division Cycle Protein 45 in Tissue Microarrays and the CDC45 Gene by Bioinformatics Analysis in Human Hepatocellular Carcinoma and Patient Outcomes.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  131. Signature of prognostic epithelial-mesenchymal transition related long noncoding RNAs (ERLs) in hepatocellular carcinoma.2021MedicineFree full text
  132. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in detecting hepatocellular carcinoma: A meta-analysis.2021MedicineFree full text
  133. Identification of potential biomarkers of peripheral blood mononuclear cell in hepatocellular carcinoma using bioinformatic analysis: A protocol for systematic review and meta-analysis.2021MedicineFree full text
  134. Efficacy of the association liver partition and portal vein ligation for staged hepatectomy for the treatment of solitary huge hepatocellular carcinoma: a retrospective single-center study.2021World journal of surgical oncologyFree full text
All its trials on ClinicalTrials.gov, any status11
  1. Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor ThrombusStatus unknownNCT06040177Lead sponsorPhase 1/Phase 2Start 2023-02
  2. A Study of DC-CIK to Treat Hepatocellular CarcinomaStatus unknownNCT01821482Lead (inferred)Phase 2Start 2013-05
  3. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951Study siteStart 2026-07
  4. A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT07478302Study sitePhase 1Start 2026-04
  5. TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal HypertensionNot yet recruitingNCT07350070Study sitePhase 2Start 2025-12
  6. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09
  7. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  8. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  9. YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)CompletedNCT04000737Study sitePhase 2Start 2020-01
  10. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  11. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) SubjectsTerminatedNCT03591965Study sitePhase 2Start 2018-08

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 46 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.5%.

Papers led
46
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 5520212022: 131320222023: 5520232024: 111120242025: 12122025

2 hospitals in Nanning for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07552402

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AINutrition & recoveryPeritoneal spread & advanced disease
Departments in papersPathology / laboratory medicineRadiology / nuclear medicineGastroenterology / hepatologyMedical oncology
Papers it led46
  1. Development and Validation of an AI-Based Multimodal Model for Pathological Staging of Gastric Cancer Using CT and Endoscopic Images.2025Academic radiology
  2. Comprehensive multi-omics pan-cancer analysis revealed EGFLAM as a potential prognostic and immune infiltration-associated biomarker.2025BMC cancerFree full text
  3. Comparison of outcomes between surgery and non-surgery after conversion therapy for advanced gastric cancer with unresectable factors: a systematic review and meta-analysis.2025BMC gastroenterologyFree full text
  4. Unveiling the heterogeneity and immunotherapy potency of tumor-associated neutrophils in the tumor microenvironment of gastric cancer.2025BMC gastroenterologyFree full text
  5. Transcription Factor MYB Upregulates IQGAP3 to Mediate DNA Repair and Promote 5-FU Resistance in Gastric Cancer Cells.2025Drug development research
  6. Exploring NUP62's role in cancer progression, tumor immunity, and treatment response: insights from multi-omics analysis.2025Frontiers in immunologyFree full text
  7. CLIC1 regulates cellular oxidative stress and gastric cancer progress by enhancing ACOX1 ubiquitination.2025International journal of biological macromolecules
  8. Exosome-derived Menin from cancer-associated fibroblasts promotes gastric cancer progression by activating the HSPA6/JNK/JunD pathway and inducing EMT.2025Journal of translational medicineFree full text
  9. The CLIC1-PKM2 axis orchestrates glycolytic metabolism to accelerate gastric cancer progression.2025Journal of translational medicineFree full text
  10. Body Composition Decrease and Impact on Clinical Outcome in Gastric Cancer Patients Undergoing Radical Gastrectomy After Neoadjuvant Treatment.2025Nutrition and cancer
  11. Integrating visceral protein ratios and mid-arm circumference predicts survival and malnutrition in gastric cancer.2025Scientific reportsFree full text
  12. Prognostic significance of anthropometric measurements in gastric cancer: a multicenter cohort study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  13. CLIC1-mediated autophagy confers resistance to DDP in gastric cancer.2024Anti-cancer drugsFree full text
  14. Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma.2024Anti-cancer drugs
  15. A nomogram for predicting nutritional risk before gastric cancer surgery.2024Asia Pacific journal of clinical nutritionFree full text
  16. Development and validation of a Radiopathomics model based on CT scans and whole slide images for discriminating between Stage I-II and Stage III gastric cancer.2024BMC cancerFree full text
  17. Human blood metabolites and gastric cancer: a Mendelian randomization analysis.2024BMC gastroenterologyFree full text
  18. Identification of CERS5 as a molecular biomarker in pan-cancer through multiple omics integrative analysis.2024Cellular signalling
  19. Predicting malnutrition in gastric cancer patients using computed tomography(CT) deep learning features and clinical data.2024Clinical nutrition (Edinburgh, Scotland)
  20. Anoikis-related genes as potential prognostic biomarkers in gastric cancer: A multilevel integrative analysis and predictive therapeutic value.2024IET systems biologyFree full text
  21. Predictive value of prognostic nutritional index in patients undergoing gastrectomy for gastric cancer: A systematic review and meta-analysis.2024MedicineFree full text
  22. Prevalence and unfavorable outcome of frailty in older adults with gastric cancer: a systematic review and meta-analysis.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  23. Application of the quality of recovery-40 questionnaire to evaluate the effectiveness of enhanced recovery after surgery protocols in gastric cancer.2024Updates in surgeryFree full text
  24. Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer.2023BMC cancerFree full text
  25. Elian granules alleviate precancerous lesions of gastric cancer in rats by suppressing M2-type polarization of tumor-associated macrophages through NF-κB signaling pathway.2023BMC complementary medicine and therapiesFree full text
  26. Construction of an autophagy-related eleven long noncoding RNA signature to predict the outcomes, immune cell infiltration, and immunotherapy response in patients with gastric cancer.2023Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  27. Pan-cancer analysis of the prognostic significance and oncogenic role of GXYLT2.2023Medicine
  28. Feasibility of olfactomedin 4 as a molecular biomarker for early diagnosis of gastric neoplasia after intestinal metaplasia.2023Scandinavian journal of gastroenterology
  29. Comparison of clinical-computed tomography model with 2D and 3D radiomics models to predict occult peritoneal metastases in advanced gastric cancer.2022Abdominal radiology (New York)
  30. Radiomics in Addition to Computed Tomography-Based Body Composition Nomogram May Improve the Prediction of Postoperative Complications in Gastric Cancer Patients.2022Annals of nutrition & metabolism
  31. DEAD-box helicase 56 functions as an oncogene promote cell proliferation and invasion in gastric cancer via the FOXO1/p21 Cip1/c-Myc signaling pathway.2022BioengineeredFree full text
  32. Tumor-derived extracellular vesicles shuttle c-Myc to promote gastric cancer growth and metastasis via the KCNQ1OT1/miR-556-3p/CLIC1 axis.2022Cell death & diseaseFree full text
  33. Comment on Granieri et al. "Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials".2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  34. Association of polymorphisms in PIN1 with progression and susceptibility in gastric cancer.2022Future oncology (London, England)
  35. Circ_0008287 promotes immune escape of gastric cancer cells through impairing microRNA-548c-3p-dependent inhibition of CLIC1.2022International immunopharmacology
  36. ITGA5 Promotes Tumor Progression through the Activation of the FAK/AKT Signaling Pathway in Human Gastric Cancer.2022Oxidative medicine and cellular longevityFree full text
  37. Mechanism of Elian granules in the treatment of precancerous lesions of gastric cancer in rats through the MAPK signalling pathway based on network pharmacology.2022Pharmaceutical biologyFree full text
  38. Construction of a novel signature and prediction of the immune landscape in gastric cancer based on necroptosis-related genes.2022Scientific reportsFree full text
  39. Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer.2022The International journal of biological markers
  40. SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation.2022TrialsRCTFree full text
  41. The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials.2022Updates in surgery
  42. Diagnostic Values of the Prealbumin-to-Fibrinogen, Albumin-to-Fibrinogen, and Monocyte-to-Lymphocyte Ratios in Gastric Cancer.2021Annals of clinical and laboratory science
  43. α-Actinin1 promotes tumorigenesis and epithelial-mesenchymal transition of gastric cancer via the AKT/GSK3β/β-Catenin pathway.2021BioengineeredFree full text
  44. CLIC1 knockout inhibits invasion and migration of gastric cancer by upregulating AMOT-p130 expression.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  45. Integrated analysis identifies oxidative stress genes associated with progression and prognosis in gastric cancer.2021Scientific reportsFree full text
  46. Effects of Laparoscopic Radical Gastrectomy on Peritoneal Micrometastases of Gastric Cancer.2021Surgical laparoscopy, endoscopy & percutaneous techniques
All its trials on ClinicalTrials.gov, any status1
  1. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Study siteN/AStart 2026-06

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Nanning for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Nanning for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 37 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.6%.

Papers led
37
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 101020222023: 121220232024: 5520242025: 662025

12 hospitals in Nanning for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led37
  1. GSH-responsive Pt-based nanomotor with improved doxorubicin delivery for synergistic osteosarcoma chemotherapy.2025Acta biomaterialia
  2. N-terminal histone acetyltransferase NAA40 modulates osteosarcoma progression by controlling AGR2 expression.2025Biochemical and biophysical research communications
  3. Hsa_circ_0002005 aggravates osteosarcoma by increasing cell proliferation, migration, and invasion.2025Gene
  4. NFATC3 enhances osteosarcoma progression by increasing PD-L1 and CXCL2 levels.2025Medical oncology (Northwood, London, England)
  5. Formononetin enhances cisplatin chemotherapy sensitivity in osteosarcoma by inducing ferroptosis and reconstructing the immune microenvironment.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  6. Prognostic significance of T cells and NK cells in osteosarcoma: a dual-center retrospective study.2025World journal of surgical oncology
  7. Single-cell and spatial transcriptomics reveal metastasis mechanism and microenvironment remodeling of lymph node in osteosarcoma.2024BMC medicine
  8. A Case of Non-calcified Intrahepatic Primary Osteosarcoma: A Case Report and a Literature Review.2024Current medical imaging
  9. Development of a Risk Model and Genotyping Patterns Based on Disulfidptosis-Related lncRNAs to Predict Prognosis and Immune Landscape in Osteosarcoma.2024Frontiers in bioscience (Landmark edition)
  10. Development and validation of neutrophil extracellular traps-derived signature to predict the prognosis for osteosarcoma patients.2024International immunopharmacology
  11. Investigation of cellular communication and signaling pathways in tumor microenvironment for high TP53-expressing osteosarcoma cells through single-cell RNA sequencing.2024Medical oncology (Northwood, London, England)
  12. Identification and verification of a BMPs-related gene signature for osteosarcoma prognosis prediction.2023BMC cancer
  13. Pan-Cancer analysis of TERT and Validation in Osteosarcoma Cell Lines.2023Biochemical and biophysical research communications
  14. Hsa_circ_0007031 promotes the proliferation and migration of osteosarcoma cells by sponging miR-196a-5p to regulate the HOXB6.2023Biochemical pharmacology
  15. FAM60A promotes osteosarcoma development and progression.2023Cancer medicine
  16. Interaction gene set between osteoclasts and regulatory CD4+ T cells can accurately predict the prognosis of patients with osteosarcoma.2023Cancer science
  17. Circ_0001060 Upregulates and Encourages Progression in Osteosarcoma.2023DNA and cell biology
  18. A new insight of immunosuppressive microenvironment in osteosarcoma lung metastasis.2023Experimental biology and medicine (Maywood, N.J.)
  19. Analysis of scRNA-seq and bulk RNA-seq demonstrates the effects of EVI2B or CD361 on CD8+ T cells in osteosarcoma.2023Experimental biology and medicine (Maywood, N.J.)
  20. A novel molecular signature for predicting prognosis and immunotherapy response in osteosarcoma based on tumor-infiltrating cell marker genes.2023Frontiers in immunology
  21. Exosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1.2023Molecular cancer
  22. Long non-coding RNA and circular RNA and coding RNA profiling of plasma exosomes of osteosarcoma by RNA seq.2023Scientific data
  23. RhRu Alloy-Anchored MXene Nanozyme for Synergistic Osteosarcoma Therapy.2023Small (Weinheim an der Bergstrasse, Germany)
  24. Efficacy of Diffusion-Weighted Imaging in Neoadjuvant Chemotherapy for Osteosarcoma: A Systematic Review and Meta-Analysis.2022Academic radiology
  25. A new model of preoperative systemic inflammatory markers predicting overall survival of osteosarcoma: a multicenter retrospective study.2022BMC cancer
  26. Significance of the neutrophil-to-lymphocyte ratio in predicting the response to neoadjuvant chemotherapy in extremity osteosarcoma: a multicentre retrospective study.2022BMC cancer
  27. PLCE1 is a poor prognostic marker and may promote immune escape from osteosarcoma by the CD70-CD27 signaling pathway.2022Bosnian journal of basic medical sciences
  28. Identification of Candidate MicroRNA-mRNA Subnetwork for Predicting the Osteosarcoma Progression by Bioinformatics Analysis.2022Computational and mathematical methods in medicine
  29. Construction of a transcription factor-miRNA-mRNA interactive network elucidates underlying pathogenesis for osteosarcoma and validation by qRT-PCR.2022Medicine
  30. Prognostic value of preoperative P-CRP in patients with osteosarcoma: A retrospective study of 101 cases.2022Medicine
  31. Two novel predictive biomarkers for osteosarcoma and glycolysis pathways: A profiling study on HS2ST1 and SDC3.2022Medicine
  32. The regulatory mechanism of LncRNA-mediated ceRNA network in osteosarcoma.2022Scientific reports
  33. Five hypoxia and immunity related genes as potential biomarkers for the prognosis of osteosarcoma.2022Scientific reports
  34. Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.2021Cell proliferation
  35. STAT3 and its targeting inhibitors in osteosarcoma.2021Cell proliferation
  36. CCT6A, a novel prognostic biomarker for Ewing sarcoma.2021Medicine
  37. TYROBP, TLR4 and ITGAM regulated macrophages polarization and immune checkpoints expression in osteosarcoma.2021Scientific reports
Chinese-language papers (not in the count)1
  1. [Polyphyllin VII inhibits osteosarcoma xenograft growth in mice by inducing ferroptosis via upregulating SOHLH1].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical University
Earlier papers (2016–2020)16
  1. Intraperitoneal extraosseous osteosarcoma: a case report and literatures review.2020BMC musculoskeletal disorders
  2. m6A-dependent up-regulation of DRG1 by METTL3 and ELAVL1 promotes growth, migration, and colony formation in osteosarcoma.2020Bioscience reports
  3. Berberine enhances the radiosensitivity of osteosarcoma by targeting Rad51 and epithelial-mesenchymal transition.2020Journal of cancer research and therapeutics
  4. URG4 mediates cell proliferation and cell cycle in osteosarcoma via GSK3β/β-catenin/cyclin D1 signaling pathway.2020Journal of orthopaedic surgery and research
  5. Establishment of immune prognostic signature and analysis of prospective molecular mechanisms in childhood osteosarcoma patients.2020Medicine
  6. Impact of Hydrogel Elasticity and Adherence on Osteosarcoma Cells and Osteoblasts.2019Advanced healthcare materials
  7. Untangling the response of bone tumor cells and bone forming cells to matrix stiffness and adhesion ligand density by means of hydrogels.2019Biomaterials
  8. Differential expression and bioinformatics analysis of circRNA in osteosarcoma.2019Bioscience reports
  9. Expression of miR‑542‑3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways.2019Molecular medicine reports
  10. [Application of pasteurized tumor-bearing bone replantation for primary malignant bone tumor of extremities].2019Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  11. To Explore the Mechanism of the GRM4 Gene in Osteosarcoma by RNA Sequencing and Bioinformatics Approach.2018Medical science monitor basic research
  12. Acute lymphoblastic leukemia arising after treatment of Ewing sarcoma was misdiagnosed as bone marrow metastasis of Ewing sarcoma: A case report.2018Medicine
  13. Long non-coding RNA HOXA11-AS functions as a competing endogenous RNA to regulate ROCK1 expression by sponging miR-124-3p in osteosarcoma.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  14. Icarisid II inhibits the proliferation of human osteosarcoma cells by inducing apoptosis and cell cycle arrest.2017Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  15. Highly expressed ribosomal protein L34 indicates poor prognosis in osteosarcoma and its knockdown suppresses osteosarcoma proliferation probably through translational control.2016Scientific reports
  16. Association of GRM4 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma in Guangxi Chinese population.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

3 hospitals in Nanning for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Nanning for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 11 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.7%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 1120232024: 2220242025: 332025

2 hospitals in Nanning for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07258511

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an

  2. Recruiting
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07663253

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou

  3. Recruiting
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06083207

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou

  4. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  5. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskStem cell transplantDrug combinations
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine
Papers it led11
  1. Active Epstein-Barr virus infection and its association with multiple myeloma: evidence from a meta-analytical perspective.2025Hematology (Amsterdam, Netherlands)
  2. Beyond ISS staging: the prognostic value of the Inflammation Prognostic Score Index (IPSI) in multiple myeloma.2025Hematology (Amsterdam, Netherlands)
  3. Visual assessment and quantitative analysis of dual-energy CT virtual non-calcium in imaging diagnosis of multiple myeloma.2025Skeletal radiology
  4. Association between BCL2 interacting protein 3 like (BNIP3L) genetic polymorphisms and the risk of multiple myeloma in China.2024Hematology (Amsterdam, Netherlands)
  5. Correlation analysis of laboratory indicators, genetic abnormalities and staging in patients with newly diagnosed multiple myeloma.2024MedicineFree full text
  6. Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.2023Hematology (Amsterdam, Netherlands)
  7. 5-Amino-4-Imidazolecarboxamide Ribonucleotide Transformylase/IMP Cyclohydrolase Polymorphisms Affect the Susceptibility to Multiple Myeloma.2022Laboratory medicine
  8. MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.2022Leukemia research
  9. Upregulation of ATIC in multiple myeloma tissues based on tissue microarray and gene microarrays.2021International journal of laboratory hematology
  10. Integrated analysis of hub gene expression in multiple myeloma.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  11. Expression and Clinical Significance of BCL2 Interacting Protein 3 Like in Multiple Myeloma.2021Technology in cancer research & treatmentFree full text
All its trials on ClinicalTrials.gov, any status8
  1. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Study siteStart 2026-06
  2. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Study sitePhase 3Start 2026-02
  3. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  4. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT06083207Study sitePhase 1/Phase 2Start 2024-07
  5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  6. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  7. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  8. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 3 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

1 hospital in Nanning for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesLymphoma & cancer-related HLHEBV & infection triggersTreatment regimens
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 25 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 8.0%.

Papers led
25
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 6620232024: 1120242025: 11112025

9 hospitals in Nanning for beta thalassaemia157 hospitals in China for beta thalassaemia

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
    Phase
    Early phase 1
    Started
    2023-02
    Registry
    NCT05762510

    Age 5 years to 35 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 1 listed hospital as study siteNanning

  2. Recruiting
    A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
    Phase
    Phase 1
    Started
    2024-01
    Registry
    NCT06465550

    Age 3 years to 35 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Nanning, Shanghai

  3. Recruiting
    A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT06772766

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHaikou, Nanning

  4. Recruiting
    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
    Phase
    Phase 2
    Started
    2019-11
    Registry
    NCT04143724

    Age 6 years to 17 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Nanning, Shenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePediatricsPathology / laboratory medicine
Papers it led25
  1. WGCNA and LASSO regression-based selection and validation of microRNA biomarkers of β-thalassemia.2026Blood cells, molecules & diseases
  2. Whole-Brain Analysis of Increased Brain Iron in Patients with β-Thalassemia.2025Academic radiology
  3. Neuroimaging in the diagnosis and treatment of cerebral toxoplasmosis in children with severe β-thalassemia after allo-HSCT.2025Biomolecules & biomedicine
  4. Study on Large-Scale Brain Network Abnormalities in Patients With Beta-Thalassemia.2025Brain and behavior
  5. Echocardiographic Left Atrial Stiffness Index Predicts Myocardial Iron Overload in Pediatric β-Thalassemia.2025Echocardiography (Mount Kisco, N.Y.)
  6. Predictive value of hepcidin and HIF1α protein levels for iron deposition in β-thalassemia.2025European journal of pediatrics
  7. Risk factors of low bone mass in young patients with transfusion-dependent beta-thalassemia.2025Frontiers in endocrinology
  8. IGHG4: innovative diagnostic biomarkers for iron overload in β-thalassemia patients.2025Hematology (Amsterdam, Netherlands)
  9. KLF1 Knockdown Differentially Regulates γ-Globin Expression: Inhibition in K562 Cells but Reactivation in β-Thalassemia Major Erythrocytes with Erythropoiesis Disruption.2025Hemoglobin
  10. Research on iron regulatory erythroid factors in children with β-thalassemia.2025Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  11. Correlation study between magnetic resonance imaging-quantitated cardiac iron deposition and left ventricular function in patients with β-thalassemia major in China.2025Science progress
  12. White matter microstructure abnormalities in thalassemia patients using TBSS analysis based on DTI.2025Scientific reports
  13. Research on the clinical factors of cardiac iron deposition in children with beta-thalassemia major.2024European journal of pediatrics
  14. Long-term Effect of Hematopoietic Stem Cell Transplantation on the Quality of Life of Patients with β-thalassemia Major in Guangxi, China - A Cross-sectional Study.2023Current stem cell research & therapy
  15. Identification of two novel β-globin gene mutations HBB: exon3del, HBB: c.-81A>C.2023Hematology (Amsterdam, Netherlands)
  16. Molecular Basis and Hematologic Phenotype of Hemoglobin H Disease Combined with Two Rare β-Globin Mutations.2023Hemoglobin
  17. Integration of targeted sequencing and pseudo-tetraploid genotyping into clinically assisted decision support for β-thalassemia invasive prenatal diagnosis.2023PloS one
  18. Magnetic resonance imaging assessment of the changes of cardiac and hepatic iron load in thalassemia patients before and after hematopoietic stem cell transplantation.2023Scientific reports
  19. Echocardiographic evaluation of left atrial strain for predicting iron overload in pediatric patients with β-thalassemia with preserved ejection fraction.2023The international journal of cardiovascular imaging
  20. Health-related quality of life in pediatric patients with β-thalassemia major after hematopoietic stem cell transplantation.2022Bone marrow transplantation
  21. Analysis of circRNAs and circRNA-associated competing endogenous RNA networks in β-thalassemia.2022Scientific reports
  22. Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome.2021Bone marrow transplantation
  23. Quality of Life in Patients with β-thalassemia Major: Short-term and Long-term Effects After Haematopoietic Stem Cell Transplantation.2021Current stem cell research & therapy
  24. Spectrum of β-Thalassemia Mutations in Some Areas of Guangxi Zhuang Autonomous Region of Southern China: A Study on a Pediatric Population Aged 0-15 Years.2021Hemoglobin
  25. Initial Dosage Optimization of Tacrolimus in Pediatric Patients With Thalassemia Major Undergoing Hematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics.2021The Annals of pharmacotherapy
Earlier papers (2016–2020)15
  1. A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload.2020British journal of haematology
  2. Hereditary spherocytosis overlooked for 7 years in a pediatric patient with β-thalassemia trait and novel compound heterozygous mutations of SPTA1 gene.2020Hematology (Amsterdam, Netherlands)
  3. Compound Heterozygosity for a Novel Mutation Codon 104 (-A) (HBB: c.313delA) and Codons 41/42 (-CTTT) (HBB: c.126_129delCTTT) Leading to β-Thalassemia Major in a Chinese Family.2020Hemoglobin
  4. A Novel Mutation at HBB: c.91delA (Codon 30, -A) Causing β-Thalassemia in a Chinese Family.2019Acta haematologica
  5. G-CSF-Mobilized Blood and Bone Marrow Grafts as the Source of Stem Cells for HLA-Identical Sibling Transplantation in Patients with Thalassemia Major.2019Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  6. Immune recovery after in vivo T-cell depletion myeloablative conditioning hematopoietic stem cell transplantation in severe beta-thalassemia children.2019European journal of haematology
  7. Construction and Analysis of a Long Non-Coding RNA (lncRNA)-Associated ceRNA Network in β-Thalassemia and Hereditary Persistence of Fetal Hemoglobin.2019Medical science monitor : international medical journal of experimental and clinical research
  8. BCL11A Down-Regulation Induces γ-Globin in Human β-Thalassemia Major Erythroid Cells.2018Hemoglobin
  9. ARHGAP18 is a novel gene under positive natural selection that influences HbF levels in β-thalassaemia.2018Molecular genetics and genomics : MGG
  10. Alterations of anticoagulant proteins and soluble endothelial protein C receptor in thalassemia patients of Chinese origin.2018Thrombosis research
  11. SOX6 Downregulation Induces γ-Globin in Human β-Thalassemia Major Erythroid Cells.2017BioMed research international
  12. A Novel Variant with Positive Natural Selection Influenced Hb A2 Levels in Chinese Individuals with β-Thalassemia.2017Hemoglobin
  13. Genome-wide analysis of aberrantly expressed lncRNAs and miRNAs with associated co-expression and ceRNA networks in β-thalassemia and hereditary persistence of fetal hemoglobin.2017Oncotarget
  14. The prevalence of thalassemia in mainland China: evidence from epidemiological surveys.2017Scientific reports
  15. Prevalence of diabetes mellitus in Chinese children with thalassaemia major.2017Tropical medicine & international health : TM & IH
All its trials on ClinicalTrials.gov, any status15
  1. A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]RecruitingNCT05762510Lead sponsorEarly phase 1Start 2023-02
  2. A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-ThalassemiaStatus unknownNCT06678165Lead sponsorEarly phase 1Start 2024-12
  3. Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical StudyCompletedNCT04009525Lead sponsorPhase 4Start 2019-07
  4. Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia MajorStatus unknownNCT03171831Lead sponsorPhase 4Start 2017-04
  5. Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of ChimerismStatus unknownNCT03101423Lead sponsorN/AStart 2016-08
  6. A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia MajorRecruitingNCT06465550Study sitePhase 1Start 2024-01
  7. A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemiaRecruitingNCT06772766Study sitePhase 1Start 2024-12
  8. Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaRecruitingNCT04143724Study sitePhase 2Start 2019-11
  9. A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia MajorNot yet recruitingNCT07489196Study sitePhase 2Start 2026-04
  10. A Long-term Follow-up Study in Participants Who Received CS-101Enrolling by invitationNCT06685536Study siteStart 2025-01
  11. A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 InjectionEnrolling by invitationNCT06717932Study siteStart 2025-05
  12. A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia MajorCompletedNCT06291961Study sitePhase 1Start 2024-04
  13. CS-101 in Patients With β-thalassemiaEnrolling by invitationNCT06328764Study siteEarly phase 1Start 2024-03
  14. A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemiaCompletedNCT06024876Study siteEarly phase 1Start 2023-08
  15. Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaActive, not recruitingNCT05577312Study sitePhase 1/Phase 2Start 2022-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 2 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Nanning for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicinePediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 3 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

1 hospital in Nanning for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosisImagingPregnancy, children, older adults
Departments in papersNeurologyOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 5 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.0%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 332025

1 hospital in Nanning for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosisBiologic & complement drugsStandard immunotherapy
Departments in papersNeurology

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 4 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 1.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

1 hospital in Nanning for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & blood flowRevascularisation surgeryStroke & bleeding outcomes
Departments in papersNeurologyNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 11 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 4.2%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 3320232024: 3320242025: 112025

2 hospitals in Nanning for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led11
  1. Elevated Release of Presynaptic Glutamate: The Potential Pathogenesis of Anti-NMDAR Encephalitis-Associated Seizures.2025CNS neuroscience & therapeutics
  2. Abnormal global and local connectivity in patients with anti-N-methyl-D-aspartate receptor encephalitis: A resting-state functional MRI study.2024Brain research
  3. Identifying the Anti-inflammatory Effects of Astragalus Polysaccharides in Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Network Pharmacology and Experimental Validation.2024Combinatorial chemistry & high throughput screening
  4. The P38MAPK Pathway Mediates the Destruction of the Blood-Brain Barrier in Anti-NMDAR Encephalitis Mice.2024Neurochemical research
  5. Abnormalities in modular connectivity of functional brain networks and cognitive changes in patients with anti -N-methyl-D-aspartate receptor encephalitis.2023Brain research
  6. Inhibiting PI3K/Akt-Signaling Pathway Improves Neurobehavior Changes in Anti-NMDAR Encephalitis Mice by Ameliorating Blood-Brain Barrier Disruption and Neuronal Damage.2023Cellular and molecular neurobiology
  7. The alterations of spontaneous neural activities and white matter microstructures in anti-N-methyl-D-aspartate receptor encephalitis: a resting-state fMRI and DTI study.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  8. Correlation analysis between regional homogeneity and executive dysfunction in anti-N-methyl-D-aspartate receptor encephalitis patients.2022European journal of neurology
  9. Aberrant resting-state interhemispheric functional connectivity in patients with anti-N-methyl-D-aspartate receptor encephalitis.2022Neuroradiology
  10. The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity.2021Multiple sclerosis and related disorders
  11. Clinical characteristics and long-term prognosis of relapsing anti-N-methyl-D-aspartate receptor encephalitis: a retrospective, multicenter, self-controlled study.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Earlier papers (2016–2020)3
  1. Cerebral functional activity and connectivity changes in anti-N-methyl-D-aspartate receptor encephalitis: A resting-state fMRI study.2020NeuroImage. Clinical
  2. Voxel-based analysis and multivariate pattern analysis of diffusion tensor imaging study in anti-NMDA receptor encephalitis.2020Neuroradiology
  3. Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.2016Journal of neurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 2 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

2 hospitals in Nanning for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led2
  1. Formation of Multiple Intracranial Aneurysms Caused by Takayasu Arteritis.2024Radiology
  2. The diagnostic value of FDG PET/CT in Takayasu arteritis.2022Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Nanning for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led1
  1. A Novel 5-Methylcytosine- and Immune-Related Prognostic Signature Is a Potential Marker of Idiopathic Pulmonary Fibrosis.2022Computational and mathematical methods in medicine
Earlier papers (2016–2020)1
  1. Expression of GR-α and HDAC2 in steroid-Sensitive and steroid-Insensitive interstitial lung disease.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
All its trials on ClinicalTrials.gov, any status1
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Nanning for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

2 hospitals in Nanning for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Nanning for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 112025

4 hospitals in Nanning for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyRadiology / nuclear medicinePediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Nanning for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

1 hospital in Nanning for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Nanning for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Nanning for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

广西医科大学第一附属医院

First Affiliated Hospital of Guangxi Medical University

南宁

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
first Affiliated Hospital of Guangxi Medical University; First Affiliated Hospital of Guangxi Medical; First Affiliated Hospital of Guangxi Medical University Nanning

Suggest a correctionDownload the data